Loading organizations...
§ Private Profile · 840 Summer St Suite 001 South Boston, MA 02127 United States
Parallel Fluidics is a technology company.
Parallel Fluidics specializes in rapid manufacturing for microfluidics, providing an on-demand service that accelerates the prototyping and production of complex designs. The company's platform allows scientific teams to quickly iterate from concept to functional devices, significantly shortening development cycles. They deliver ultra-precise microfluidic components, often utilizing materials suitable for final product integration.
Details regarding the specific individuals who founded Parallel Fluidics and the precise moment of its inception are not readily available from current information. The company operates out of Boston, Massachusetts, serving the needs of the life sciences community from this hub.
Parallel Fluidics primarily serves research and development teams across the life sciences sector, providing essential tools for scientific discovery. The company envisions a future where the barriers to microfluidic innovation are significantly reduced, empowering researchers to advance their work on next-generation life science technologies with greater speed and efficiency.
Parallel Fluidics has raised $8.8M across 2 funding rounds.
Parallel Fluidics has raised $8.8M in total across 2 funding rounds.
Parallel Fluidics has raised $8.8M in total across 2 funding rounds.
Parallel Fluidics's investors include J2 Ventures.
Parallel Fluidics has raised $8.8M across 2 funding rounds. Most recently, it raised $7.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 7, 2024 | $7M Seed | J2 Ventures | — | Announced |
| Nov 23, 2021 | $1.8M Venture Round | — | — | Announced |
Parallel Fluidics is a Boston-based technology company specializing in rapid, on-demand manufacturing of custom microfluidic devices for the life sciences sector, including diagnostics, drug discovery, precision medicine, sequencing, and cell therapy.[1][2][4] It builds production-grade thermoplastic microfluidic chips and components—featuring channels as small as 50 micrometers—using its proprietary transition molding process, which enables prototypes in as little as 3 days and quotes in 24 hours, 10x faster than traditional injection molding.[1][3][4][6] The company serves scientific teams and engineers developing next-generation life science tools, solving key pain points like slow prototyping, high development risks, and engineering challenges in flow control, automation, and chip-to-world interfaces by offering embedded hardware libraries (e.g., the MV-2 microvalve for point-of-care use) and scalable production from prototypes to thousands of units.[2][3][4] With a recent $7M seed round, Parallel Fluidics is accelerating its manufacturing service, hardware expansion, and software for design and analytics, driving growth momentum in a market hungry for faster innovation.[2]
Parallel Fluidics was founded by Joshua Gomes (CEO) and an unnamed co-founder, with Andy Harris as COO, to address bottlenecks in microfluidic development for life science tools.[2][5] Gomes, recognizing that scientists waste time on non-core challenges like microfluidics manufacturing despite its critical role—likened to "a computer chip but with liquids instead of electrons"—launched the company to provide the world's first on-demand service for production-grade devices from day one.[2][5] Based in Boston, Massachusetts (840 Summer Street, Suite 001), it emerged from the need to shorten the path from concept to market, leveraging in-house transition molding with thermoplastics like CYROLITE® MD, COC, COP, PMMA, and PC.[1][4][6] Early traction came from partnerships (e.g., with Röhm for molding compounds) and customer wins in blood testing, sensors, and biotech prototyping, validated by testimonials praising week-long turnarounds and reliable performance.[1][4] A pivotal $7M seed round in late 2024 fueled scaling, backed by investors including Praxis, J2 Ventures, and Protolabs alumni on the board.[2][5]
Parallel Fluidics stands out in microfluidics manufacturing through these key advantages:
Parallel Fluidics rides the surging demand for microfluidics in life sciences, enabling "lab-on-a-chip" innovations that miniaturize diagnostics, accelerate drug discovery, and support precision medicine amid rising needs for faster disease detection and therapies.[1][2][5] Timing is ideal: as more products incorporate microfluidics, legacy manufacturing lags with weeks-long cycles and high costs, but Parallel's on-demand model lowers entry barriers, boosts iteration speed, and bridges prototyping to scale—critical in a post-pandemic push for point-of-care tools and scalable biotech.[2][3][6] Market forces like thermoplastic advancements (e.g., CYROLITE® MD) and investor interest (evident in its seed funding) favor it, while its presence at events like MicroTAS 2024 amplifies influence.[1][6] By empowering startups and researchers—e.g., in blood testing cartridges or sensors—Parallel Fluidics democratizes access, accelerates breakthroughs, and shapes the ecosystem toward reliable, market-ready life science hardware.[4]
Parallel Fluidics is poised to dominate on-demand microfluidics with its seed-funded expansion into hardware, software, and manufacturing capacity, targeting deeper penetration in diagnostics and cell therapy.[2] Upcoming trends like AI-driven design tools, point-of-care expansion, and thermoplastic innovations will propel it, as life sciences demand ever-faster paths to scalable products amid global health pressures. Its influence could evolve from prototyping partner to full-stack platform, potentially capturing a larger share of the growing microfluidics market and inspiring similar services in adjacent fields—ultimately speeding humanity's race against disease, just as it promises from day one.[2][5]